StatLab Medical Products, a U.S.-based global developer and manufacturer of medical diagnostic supplies and equipment, is poised to acquire Diapath, an Italian manufacturer known for its expertise in histology and cytology products and equipment. This acquisition signifies a major step forward in StatLab's strategy to enhance its global presence, with a particular focus on strengthening its foothold in Europe.

Diapath, headquartered in Martinengo, near Bergamo, has established itself as a leader in the development of innovative laboratory equipment, including tissue processors, stainers, embedding centers, and microtomes. Over the years, the company has built a strong reputation in Italy and expanded its reach through subsidiaries in Germany and France, allowing it to supply advanced diagnostic solutions to laboratories across Europe. Diapath’s specialized product range and its deep understanding of the European market make it a valuable addition to StatLab’s portfolio.

Sung-Dae Hong, CEO of StatLab, emphasized the strategic importance of the acquisition, stating, “This partnership is a pivotal milestone in our efforts to provide a complete array of products supporting the entire anatomic pathology workflow. By integrating Diapath into our operations, we will be able to extend their equipment brand to global markets, including the U.S., while also significantly enhancing our access to European customers.”

The acquisition is expected to close by the third quarter of 2024. Upon completion, Diapath’s founder, Vladimiro Bergamini, will transition into a senior advisor role, ensuring continuity and guidance for future growth. Additionally, Diapath’s Chief Operating Officer, Alberto Battistel, will join StatLab’s executive leadership team.

This acquisition underscores Italy's growing importance in the global medical diagnostics industry and highlights the critical role Diapath plays in providing advanced pathology solutions to laboratories throughout Europe.